Bio-Rad Laboratories Class A

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO and other ETFs, options, and stocks.

About BIO

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. 

CEO
Norman D. Schwartz
CEONorman D. Schwartz
Employees
7,450
Employees7,450
Headquarters
Hercules, California
HeadquartersHercules, California
Founded
1952
Founded1952
Employees
7,450
Employees7,450

BIO Key Statistics

Market cap
7.53B
Market cap7.53B
Price-Earnings ratio
10.03
Price-Earnings ratio10.03
Dividend yield
Dividend yield
Average volume
300.78K
Average volume300.78K
High today
$279.51
High today$279.51
Low today
$275.40
Low today$275.40
Open price
$277.98
Open price$277.98
Volume
234.63K
Volume234.63K
52 Week high
$343.12
52 Week high$343.12
52 Week low
$211.43
52 Week low$211.43

Stock Snapshot

With a market cap of 7.53B, Bio-Rad Laboratories Class A(BIO) trades at $279.25. The stock has a price-to-earnings ratio of 10.03.

On 2026-04-11, Bio-Rad Laboratories Class A(BIO) stock traded between a low of $275.40 and a high of $279.51. Shares are currently priced at $279.25, which is +1.4% above the low and -0.1% below the high.

Bio-Rad Laboratories Class A(BIO) shares are trading with a volume of 234.63K, against a daily average of 300.78K.

In the last year, Bio-Rad Laboratories Class A(BIO) shares hit a 52-week high of $343.12 and a 52-week low of $211.43.

In the last year, Bio-Rad Laboratories Class A(BIO) shares hit a 52-week high of $343.12 and a 52-week low of $211.43.

BIO News

Simply Wall St 3d
The Bull Case For Bio-Rad Laboratories Could Change Following Citigroup’s Downgrade To Neutral

In early April 2026, Citigroup downgraded Bio-Rad Laboratories’ rating from “Buy” to “Neutral,” signaling a shift in analyst sentiment toward the life science a...

The Bull Case For Bio-Rad Laboratories Could Change Following Citigroup’s Downgrade To Neutral
Simply Wall St 4d
A Look At Bio-Rad Valuation After The Citi Downgrade And Price Target Cut

Citigroup’s downgrade of Bio-Rad Laboratories (BIO) from Buy to Neutral, along with a sharp cut to its price target, has put fresh attention on how investors as...

A Look At Bio-Rad Valuation After The Citi Downgrade And Price Target Cut
TipRanks 4d
Bio-Rad downgraded to Neutral from Buy at Citi

Citi analyst Patrick Donnelly downgraded Bio-Rad (BIO) to Neutral from Buy with a price target of $300, down from $375. The firm does not see a recovery path fo...

Analyst ratings

71%

of 7 ratings
Buy
28.6%
Hold
71.4%
Sell
0%

People also own

Based on the portfolios of people who own BIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.